Drug Profile
Research programme: Humabody VH antibody fragment-based therapeutics - Crescendo Biologics
Alternative Names: CB 108; CB 201 - Crescendo Biologics; T-cell enhancerLatest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Crescendo Biologics
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunomodulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Sep 2023 Crescendo Biologics has patent protection for Methods for producing optimised therapeutic molecules from transgenic animals in Europe
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 05 May 2020 Crescendo Biologics and Cancer Research UK enters into Clinical Development Partnerships agreement for CB 213 and Crescendo Biologics retains the right to advance the CB 213 program further